SHPH Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 40.60%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $1,912.22

Shuttle Pharmaceuticals Insider Trading History Chart

Shuttle Pharmaceuticals Share Price & Price History

^$0.39

+0.30 (1.20%)

As of 04/23/2024 01:00 AM ET

Days: 30 | 90 | 365

Bitcoin Rockets To Record High But Buy THIS Instead

From Paradigm Press | Ad

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

Shuttle Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/13/2023	Bette Jacobs	Director	Sell	4,157	$0.46	$1,912.22	27,064
12/29/2022	Hoek Michael Vander	CFO	Sell	2,243	$1.60	$3,588.80	3,852
12/29/2022	Peter Dritschilo	COO	Sell	3,820	$1.60	$6,112.00	6,560

The Best AI Stock to Own in the World Today is Trading for Just $25

From Banyan Hill Publishing | Ad

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him

SEC Filings (Institutional Ownership Changes) for Shuttle Pharmaceuticals (NASDAQ:SHPH)

4.58% of Shuttle Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Shuttle Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/2/2023	SG Americas Securities LLC	16,899	$33K	0.0%	N/A	0.124%
11/14/2022	Hsbc Holdings PLC	13,737	$67K	0.0%	N/A	0.103%
11/7/2022	Virtu Financial LLC	17,048	$78K	0.0%	N/A	0.128%

Data available starting January 2016

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas, SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers. The company was founded in 2012 and is based in Rockville, Maryland.

Today's Range

Now: $0.39

$0.37

$0.39

50 Day Range

MA: $0.41

$0.36

$0.46

52 Week Range

Now: $0.39

$0.35

$2.75

Volume

23,773 shs

Average Volume

123,395 shs

Market Capitalization

$6.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Shuttle Pharmaceuticals?: Shuttle Pharmaceuticals' top insider shareholders include:
Bette Jacobs (Director)
Peter Dritschilo (COO)
Hoek Michael Vander (CFO)
Learn More about top insider investors at Shuttle Pharmaceuticals.